Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

(Eds: Adding more info) New Delhi, Apr 7 () India is the biggest manufacturer of <keyword id="4751090" type="PERSON" weightage="20" keywordseo="Hydroxychloroquine">hydroxychloroquine</keyword>, the anti-malarial drug that is being touted as 'game-changer' in the fight against COVID-19 and is being aggressively sought by US President Donald Trump. The country has the capacity to quickly ramp up the output of hydroxychloroquine. Days after it added the drug to the list of more than two dozen APIs that cannot be exported while officials get a handle on how much will be needed for COVID-19 outbreak in the country, India on Tuesday agreed to lift the ban after Trump sought supplies for the US. India manufactures 70 per cent of the world's supply of hydroxychloroquine, according to Indian Pharmaceutical Alliance (IPA) secretary-general Sudarshan Jain. The country has a production capacity of 40 tonnes of hydroxychloroquine (HCQ) every month, implying 20 crore tablets of 200 mg each. And since the drug is also used to auto-immune diseases like rheumatoid arthritis and lupus, manufacturers have good production capacities that can also be ramped up. Ipca Laboratories, Zydus Cadila and Wallace Pharmaceuticals are top pharma companies manufacturing HCQ in India. Jain says the production capacity is sufficient to meet the current demand and if the need arises, the companies are committed to ramping up production. Recently, the Ministry of Health and Family Welfare had reportedly placed an order for around 10 crore tables of HCQ with Ipca laboratories and Zydus Cadila. The drug is not manufactured in developed nations such as the US because of non-existent malaria. Hydroxychloroquine is very similar to chloroquine, one of the oldest and best-known anti-malarial drugs, but with lesser side-effects. It can be bought over the counter and fairly inexpensive. But its purchase and use has been severely restricted as it was selectively used in the treatment of coronavirus because of its antiviral properties. India gets the active pharmaceutical ingredient (API) that is used to manufacture HCQ from China and supplies so far have been steady. As much as 70 per cent of all the APIs needed by India to manufacture drugs come from China. After Trump stated that the US could "retaliate" if India does not release stocks of the drug, Indian officials said exports of hydroxychloroquine and paracetamol will be allowed depending on availability of stock after meeting domestic requirements and existing orders. Last month, the US Food and Drug Administration (FDA) partially lifted a three-year-old 'import alert' on Ipca's two plants to import the medicine. Zydus Cadila has also received an order from the US. Pharma industry officials said the country has enough stock of HCQ and companies were ready to ramp up the capacity to meet domestic requirements as well as exports. On March 25, India had banned export of HCQ and added it to a list of more than two dozen APIs that can no longer be exported. India is the largest exporter of the drug. Officials said India would export the drug on a case-by-case basis after meeting all the domestic requirements. "The Government has withdrawn the restrictions on 12 products and its formulations. Various scenarios are being assessed and it will be the endeavour to meet both the domestic demand and export obligation for Paracetamol and hydroxychloroquine," Jain said. The objective is to minimise speculative buying and hoarding in these trying times and ensure balance in the distribution for patients and segments who need them, he added. In a similar vein, Indian Drug Manufacturers' Association (IDMA) Executive Director Ashok Kumar Madan said: "India needs around 24 million tablets per year as on date for the three indications --- malaria, lupus, and rheumatoid arthritis, it was being used". India currently has an annual installed capacity of around 40 metric tonnes of active pharmaceutical ingredients (APIs) of hydroxychloroquine. With this capacity, "we can make around 200 million tablets of 200 mg", he added. So this indicates that India currently has spare available capacity. Now, "we have to see how much would the country's requirements for the drug would grow for both treatment and prevention of COVID-19. The companies have already started ramping the capacity." The major API makers for the drug in the country are Zydus, Ipca and Mangalam Drugs. The major formulation makers of hydroxychloroquine are Ipca, Zydus, Wallace Pharmaceuticals, and Cipla, Madan said. India exported hydroxychloroquine API in April-January 2019-20 period worth USD 1.22 billion. During the same period exports of formulations made from hydroxychloroquine were at USD 5.50 billion. Indian Council of Medical Research (ICMR) recommended HCQ be used as a preventive medication for COVID-19 high-risk group. It has also recommended the use of the drug for those involved in the care of 'suspected or confirmed cases of the coronavirus and for asymptomatic household contacts of laboratory-confirmed patients, apart from healthcare workers who are involved in the treatment of COVID-19'. Ipca is the drug's top manufacturer globally. Each COVID-19 patient reportedly needs 14 tablet course and so the 10 crore pills ordered by the government can potentially treat over 71 lakh people. AKT RR ANZ BAL

India biggest producer of 'game-changer' hydroxychloroquine drug; has enough capacity

<ul><li>Confirmed cases of COVID-19 infection cross 12 lakhs around the globe with the number of deaths reported nearing 70,000. </li><li>The malignant virus invades more than 200 countries and the demand for drugs and medical equipment surge fast. </li><li>The anti-malarial drug <keyword id="4751090" type="PERSON" weightage="20" keywordseo="Hydroxychloroquine">Hydroxychloroquine</keyword> is seen as a game changer in treating COVID-19 infection. Here are the basics of this life-saving drug you must know.</li></ul>In a recent conversation with the Prime Minister of India, Donald Trump, the American President requested India to supply them huge quantities of Hydroxychloroquine. Addressing the press, Trump also warned of retaliation measures if India declined the request as it did to other countries in the face of perceiving a demand for the drug with the cases mounting up in the country too. What is <keyword id="8947192" type="UNKNOWN" weightage="20" keywordseo="Hydroxychloroquine-medicine">Hydroxychloroquine medicine</keyword> Hydroxychloroquine can be described as a racemic mixture comprising of R and S enantiomer. We can compare Hydroxychloroquine with chloroquine, an aminoquinoline. This is a commonly prescribed medicine in treating uncomplicated malaria, rheumatoid arthritis, systemic lupus erythematosus, and chronic discoid lupus erythematosus. Hydroxychloroquine is also used to address the prophylaxis of malaria in places where chloroquine resistance is unlikely. Developed during World War II as a derivative of quinacrine, this drug is said to have much lesser side effects. The FDA approved this drug on 18 April 1955. In the face of COVID-19 pandemic, the FDA has sanctioned an emergency authorization for hydroxychloroquine and chloroquine. This authorization gives room for the unapproved use of these drugs in treating the COVID-19 cases in the light of the critical public emergency seen around. The effectiveness of hydroxychloroquine in remedying the COVID-19 infection is yet to be proved though this drug is administered in the treatment in a large scale as on date. The American experiment Towards the end of March 2020, the US Food and Drug Administration provisionally approved the use of hydroxychloroquine in treating COVID-19 patients. Since then, the medical community in New York has been administering this drug to the novel coronavirus infected patients in combination with some other drugs. This experiment with hydroxychloroquine happening in the epicenter of the US has given a hint to Trump, the American President that this anti-malarial drug could be a game changer in treating COVID-19 infection. He said that this drug was giving successful results and if the trend continued, it would be a gift from heaven. The country had then quickly stocked up about 29 million doses of hydroxychloroquine besides asking India to supply the drug to them. India’s policy on hydroxychloroquine supplies to the world Last month, India had imposed a ban on the export of hydroxychloroquine. However, India is most likely to life the ban and clear the pending international orders for the drug after meeting the local requirements. It is also said that after perceiving the humanitarian situation of the COVID-19 scenario, the Department of Pharmaceuticals and Ministry of External Affairs will decide whether to fulfill the pending international orders for hydroxychloroquine. See Also - <a href="https://www.businessinsider.in/india/news/india-lifts-partial-ban-on-hydroxychloroquine-after-donald-trump-warns-of-retaliation-if-pm-modi-doesnt-help-the-us/articleshow/75022401.cms">India lifts partial ban on hydroxychloroquine medicine</a>

What is Hydroxychloroquine medicine and how it could be a game changer

New York, Apr 7 () A New Jersey-based generic pharmaceutical company, co-founded by two Indian-Americans has donated millions of hydroxychloroquine sulfate tablets to Louisiana, New York and Texas to help COVID19 patients.Amneal Pharmaceuticals has pledged to donate 400,000 hydroxychloroquine sulfate tablets to the State of Louisiana to help respond to the COVID-19 health emergency, according to a press release dated March 30 from Louisiana Attorney General Jeff Landry.However, the US government's top infectious disease specialist Anthony Fauci has been vocal about his concern that there is not enough evidence to suggest that Hydroxychloroquine is the drug that cures COVID19.The release said that the large donation will go toward clinical trials and patient treatment in Louisiana.Hydroxychloroquine, an old and inexpensive drug used to treat malaria, is seen as a viable therapeutic solution by President Trump to coronavirus that has so far killed more than 10,000 Americans and infected over 3.6 lakh within weeks. Bridgewater, New Jersey-headquartered Amneal was founded in 2002 by Chirag Patel and Chintu Patel, who are also the Co-CEOs. "Amneal has donated millions of hydroxychloroquine sulfate tablets in total to states other than Louisiana, including New York and Texas, and stated they will provide more as needed. The company also announced donations of products directly to hospitals across the country," the release added.The press release from the Louisiana Attorney General quoted Chirag and Chintu Patel as saying that "all of us at Amneal are committed to supporting our communities in the global fight against COVID-19. We are working with urgency to assist the hardest hit states and hospitals around the country to benefit as many patients as possible during this critical time."Amneal's hydroxychloroquine sulfate tablets are approved by the United States Food and Drug Administration (FDA) to treat malaria, rheumatoid arthritis, lupus, childhood arthritis, and other autoimmune diseases. Hydroxychloroquine is not FDA-approved for the treatment of COVID-19; but it has been identified as a possible treatment for COVID-19, and the US Government has requested its immediate availability, the release said.Landry thanked Amneal for the donation and said "it is important we all work together to help solve the COVID-19 crisis." The Louisiana State University School of Medicine is working to launch two different clinical trials using hydroxychloroquine in relation to COVID-19. One trial will utilise hydroxychloroquine on those who have significant COVID-19 disease.The other trial protocol will use and test the drug as a preventative measure for those healthcare workers on the front lines battling the epidemic. Trials will be conducted at the University Medical Center in New Orleans and at the LSU Medical School locations in Baton Rouge and Lafayette.Dean of LSUHSC School of Medicine Steve Nelson said the donation will allow them to conduct clinical trials examining how hydroxychloroquine may help clear the virus from the lungs of infected patients and to potentially help shield healthcare workers who are on the front lines treating patients."The hydroxychloroquine donation by Amneal comes at an important time. The Louisiana Board of Pharmacy has noted serious concerns over the availability of this drug and has issued specific guidance on the dispensing of the drug, including its March 25th guidance noting that it should be dispensed for COVID-19 when the prescription bears a COVID-19 diagnosis," the release said. YAS PMSPMS

Pharma company founded by Indian-Americans donates hydroxychloroquine tablets in US

<ul class="summary-list"><li>The UK government is seeking to buy 16 million <keyword id="4751090" type="PERSON" weightage="60" keywordseo="Hydroxychloroquine">hydroxychloroquine</keyword> tablets in case the drug proves to be an effective <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> treatment.</li><li>President <keyword id="6354484" type="PERSON" weightage="60" keywordseo="Donald-Trump">Donald Trump</keyword> claimed this week that he regularly takes the drug, despite it not being proven to either prevent or treat, the virus.</li><li>Scientists have warned that the anti-malarial drug could have adverse effects if self-administered.</li><li>UK scientists are carrying out tests to see if the drug could be a successful treatment.</li></ul>The UK government is seeking to purchase 16 million hydroxychloroquine tablets in case claims by Donald Trump that the anti-malarial drug is an effective treatment against the coronavirus, prove to be right.Trump on Monday said that he had been taking the drug every day for 10 days, despite medical experts warning that it is not proven to be an effective treatment for the COVID-19 virus and could have damaging effects on some patients."I take it," <a href="https://www.businessinsider.com/president-trump-says-hes-been-taking-hydroxychloroquine-2020-5?r=US&amp;IR=TIR=T" target="_blank" rel="noopener">Trump told reporters</a>. "I would've told you that three, four days ago, but we never had a chance because you never asked me the question."Prominent US doctor Dr. Manny Alvarez has described Trump's statement as "highly irresponsible." "In most hospitals including mine, we're not using chloroquine in the treatment of COVID patients at the present time, and we have one of the largest populations of COVID admissions in our medical center," he said.A spokesperson for UK Prime Minister <keyword id="6380867" type="PERSON" weightage="60" keywordseo="boris-johnson">Boris Johnson</keyword> on Tuesday sought to distance the UK government from Trump's decision, telling reporters: "It's not something which our own medical experts are recommending."However, despite this, Johnson's government is inviting offers from pharmaceutical companies to provide 16 million tablets of Hydroxychloroquine, <a href="https://www.theguardian.com/world/2020/may/19/uk-to-test-hydroxychloroqine-as-coronavirus-treatment?utm_source=POLITICO.EU&amp;utm_campaign=3b36160ced-EMAIL_CAMPAIGN_2020_05_20_06_11&amp;utm_medium=email&amp;utm_term=0_10959edeb5-3b36160ced-190121793ed-190121793" target="_blank" rel="noopener">The Guardian newspaper reports.</a>The contract will be put out to tender on Friday, with UK scientists planning to test the drug and distribute it to the general public if it proves to be an effective treatment for the virus.One source with knowledge of the contract told The Guardian that the drug was being bought in bulk in case it proved to be an effective treatment."All of the drugs being purchased can be used to treat other conditions too so they don't really go to waste if they aren't proved effective for COVID," the source said.The UK government is reportedly concerned that Trump's endorsement could trigger a worldwide shortage of the drug, which is used to treat other conditions.The request is part of a contract worth £35 million, with the UK government planning to purchase over 33 million tablets of various drugs from pharmaceutical companies, as it tries to identify potential treatments for the COVID-19 disease.<a href="https://www.businessinsider.com/jama-nejm-studies-on-hydroxychloroquine-for-coronavirus-patients-2020-5">Business Insider</a> has previously reported that two major studies found that hydroxychloroquine was not effective for treating COVID-19.Two observational studies, published in the <a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2012410">New England Journal of Medicine</a>and the <a href="https://jamanetwork.com/journals/jama/fullarticle/2766117">Journal of the American Medical Association</a>, found that from thousands of hospitalized coronavirus patients, those who got the drug did not do any better or worse than those who didn't get it.The JAMA study also found that those who received hydroxychloroquine combined with the antibiotic azithromycin had a higher rate of cardiac arrest.Read the original article on <a href="https://www.businessinsider.com/coronavirus-uk-buying-donald-trump-hydroxychloroquine-tablets-treatment-covid-malaria-2020-5">Business Insider</a>

The UK is bulk-buying millions of hydroxychloroquine tablets in case Trump is right that it works against the coronavirus

New Delhi, Apr 23 () The government plans to ensure supply of around 15.40 crore Hydroxychloroquine (HCQ) tablets, used in treating coronavirus infections, in the domestic market in April, an official said on Thursday.The government also plans to export HCQ medicine to 62 countries after ensuring strategic storage of the medicine for domestic use. "In normal conditions, the monthly requirement for HCQ medicine is around 2 to 2.5 crore tablets in the country. However, in the month of April, 2020 we have planned to supply around 7.5 crore tablets for retail pharmacies/ trade," an official told .Further, 6.75 crore tablets would be provided to the Centre against a requirement of 1.5 crore tablets this month. Besides, 80 lakh tablets to different state governments and 45 lakh tablets to various government institutes like ESIC and BPPI would be provided, according to the official. "Thus, (around) 15.40 crore HCQ tables will be provided in the domestic market in April, 2020," the official said. The official also said that for rationalisation of HCQ, it has prepared a weekly supply plan and the surplus medicine, after procurement by domestic market and strategic storage, is only being exported.India has started export of two very critical drugs required during the treatment of coronavirus disease -- HCQ and Paracetamol.These drugs are being provided to other countries through MEA (Ministry of External Affairs) Diplomatic Route.The official said India has plans to provide HCQ medicine to 62 countries and paracetamol to around 90 countries. Around 125 countries would get supplies of these medicines from India, the official added.On Wednesday, the government asked all state drug controllers to ensure availability of essential medicines and medical devices required in the treatment of COVID-19.In a meeting with the state drug controllers, Union Pharma Secretary P D Vaghela had asked them "to provide all support to manufacturing units with the help of local administration and concerned authorities by regular interaction so that there is no shortage of medicines and medical devices". They were also requested to ensure the utilisation of manufacturing capacity to full extent so that sufficient stocks without any hindrance can be made available at all levels. NAM NAM ANUANU

Govt plans supply of around 15.40 cr Hydroxychloroquine tablets in domestic market in April

By Lalit K Jha Washington, Apr 8 () An Indian American-owned pharma firm has pledged to donate 3.4 million Hydroxychloroquine Sulphate tablets to some of the key COVID-19 battleground states, including New York and Louisiana, joining the war against the dreaded coronavirus which by Tuesday had taken lives of more than 12,800 people in the US alone. Owned by philanthropic billionaire Chirag and Chintu Patel, New Jersey-based Amneal Pharmaceuticals, which is one of the largest US-based manufacturers, has also announced ramping up production of Hydroxychloroquine Sulphate at several of its manufacturing sites and expects to produce approximately 20 million tablets between now and mid-April.Those tablets will be made available nationwide through Amneal's existing retail and wholesale customers, as well as through direct sales to larger institutions in need, the company said. Amneal has donated two million tablets of 200mg Hydroxychloroquine Sulphate to New York, and one million to Texas to be used in the treatment of COVID-19 patients. It is ready to provide more as needed. It is also donating and providing products directly to hospitals across the country, the company said. Amneal has also announced donation of 400,000 Hydroxychloroquine Sulphate tablets to Louisiana."All of us at Amneal are committed to supporting our communities in the global fight against COVID-19," said Chirag and Chintu Patel, Co-Chief Executive Officers of Amneal."We are working with urgency to assist the hardest hit states and hospitals around the country to benefit as many patients as possible during this critical time," they said in a joint statement, issued by the Louisiana Attorney General Jeff Landry."It is important we all work together to help solve the COVID-19 coronavirus crisis. We must come together as Louisianans and as Americans. This donation from Amneal demonstrates their strong effort to be a good corporate citizen in our nation," Landry said.Hydroxychloroquine Sulphate was first synthesized in 1946 and is in a class of medications historically used to treat and prevent malaria. According to Louisiana State Government, Amneal's Hydroxychloroquine Sulphate tablets are approved by the US Food and Drug Administration to treat malaria, rheumatoid arthritis, lupus, childhood arthritis, and other autoimmune diseases. Hydroxychloroquine is not FDA-approved for the treatment of COVID-19; but it has been identified as a possible treatment for it, and the US government has requested its immediate availability."This is a crucial time in the global fight against COVID-19," Chirag and Chintu Patel said in a company press release."With an existing supply of Hydroxychloroquine Sulphate and our ability to quickly accelerate production, we are humbled to be able to assist the hardest hit states and hospitals around the country to benefit as many patients as possible," the two brothers said. Landry said that Amneal's donation is one step toward trying to find treatments and cures for this epidemic. "Right now, there are no silver bullets. We must remain vigilant against the spread of this virus," he said.The Louisiana State University School of Medicine is working to launch two different clinical trials using hydroxychloroquine in relation to COVID-19. One trial will utilize Hydroxychloroquine on those who have significant COVID-19 disease. The other trial protocol will use and test the drug as a preventative measure for those healthcare workers on the front lines battling the epidemic. Trials will be conducted at the University Medical Center in New Orleans and at the LSU Medical School locations in Baton Rouge and Lafayette, a media release said. LKJ RAXRAX

Indian American's US pharma firm donates 3.4 M Hydroxychloroquine Sulphate tablets

New Delhi, Apr 10 () The government on Friday said that there is enough stock of hydroxychloroquine in the country and it is taking all steps to ensure that there is no shortage of the drug in the domestic market. India is the biggest manufacturer of the anti-malarial drug that is being touted as 'game changer' in the fight against the COVID-19 pandemic. "There is enough stock of hydroxychloroquine in the country and we are tracking its demand, availability and production on a daily basis," National Pharmaceutical Pricing Authority (NPPA) Chairman Shubhra Singh told . India is the world's largest manufacturer of the drug, which is used for treatment of rheumatoid arthritis, malaria and lupus, she added. "Ensuring the availability of the drug in the country is our first priority. Only after meeting the demand here, the exports are being done," Singh said. She, however, cautioned that the medicine should only be taken on the advice of doctors. India manufactures 70 per cent of the world's supply of hydroxychloroquine. Companies like IPCA and Zydus Cadila are the major manufacturers of hydroxychloroquine in the country. The Indian pharmaceutical industry earlier this week said there is enough stock of hydroxychloroquine in the country and drug firms are ready to ramp up the production to meet domestic as well as export requirements. India currently has an annual installed capacity of around 40 tonnes of active pharmaceutical ingredients (APIs) of hydroxychloroquine. With this capacity, it can make around 200 million tablets of 200 mg, which can be ramped up, the Indian Drug Manufacturers' Association (IDMA) had said. The production capacity in the country is sufficient to meet the current demand. If the need arises, the companies are committed to ramp up production, the Indian Pharmaceutical Alliance had earlier told . India on Tuesday had decided to partially lift the ban on the export of anti-malarial drug hydroxychloroquine in sync with its global commitment to deal with the coronavirus pandemic. AKT HRS

Enough stock of hydroxychloroquine in India: Govt

A consignment of hydroxychloroquine from India arrived in the United States on Saturday, days after New Delhi lifted a ban on export of the anti-malaria drug, seen as a possible cure for COVID-19, to the US and some other countries on humanitarian grounds. Earlier this week, India at the request of President Donald Trump cleared the export of 35.82 lakh tablets of hydroxychloroquine to the US along with nine metric tons of active pharmaceutical ingredient or API required in the manufacturing of the drug. "Supporting our partners in the fight against COVID-19. Consignment of hydroxychloroquine from India arrived at Newark airport today," India's Ambassador to the US Taranjit Singh Sandhu tweeted. Trump, during a phone call last week, asked Prime Minister Narendra Modi to lift the hold on American order of the anti-malarial drug, of which India is the major producer. India, which manufactures 70 per cent of the world's supply of hydroxychloroquine, lifted the ban on April 7. Hydroxychloroquine has been identified by the US Food and Drug Administration as a possible treatment for the COVID-19 and it is being tested on more than 1,500 <keyword id="1754604" type="PERSON" weightage="20" keywordseo="coronavirus">coronavirus</keyword> patients in <keyword id="6355838" type="LOCATION" weightage="20" keywordseo="new-york">New York</keyword>. Anticipating that it will work, given initial positive results, Trump has bought more than 29 million doses of hydroxychloroquine for potential treatment of COVID-19 patients. The arrival of consignment was welcomed by Americans. "US will never forget this great humanitarian gesture by India. Under President Trump and Prime Minister Narendra Modi, the two largest democracies of the world have come together than ever in the past, said New York-based Al Mason, a real estate consultant and a Trump supporter. A wonderful gesture by India to its friends in need, tweeted Dr Sampat Shivangi. Describing this as a wonderful gesture , Steve Filipovic, who works in the construction industry, thanked the Indian Ambassador. Meanwhile, according to a new French study of 1,061 hospitalised COVID-19 patients showed a 91.7 per cent cure (viral shedding) within 10 days of hydroxychloroquine treatment along with anti-biotic. It also reported a 96 per cent cure rate after 15 days. Early this week, the National Institute of Health reported that a clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalised with the coronavirus disease 2019 (COVID-19) has begun, with the first participants now enrolled in Tennessee. Hydroxychloroquine is used to treat malaria and rheumatoid conditions such as arthritis. In various studies, the drug has demonstrated antiviral activity, an ability to modify the activity of the immune system, and has an established safety profile at appropriate doses, leading to the hypothesis that it may also be useful in the treatment of COVID-19, NIH said. The drug is not without risks as even short-term use can cause cardiac arrythmias, seizures, dermatological reactions, and hypoglycemia, it added. Many US hospitals are currently using hydroxychloroquine as first-line therapy for hospitalized patients with COVID-19 despite extremely limited clinical data supporting its effectiveness, said Wesley Self, emergency medicine physician at Vanderbilt University Medical Center and PETAL Clinical Trials Network investigator leading the ORCHID trial. Thus, data on hydroxychloroquine for the treatment of COVID-19 are urgently needed to inform clinical practice, he added. According to NIH, participants will be randomly assigned to receive hydroxychloroquine 400 mg twice daily for two doses (day one), then 200 mg twice daily for the subsequent eight doses (days two to five) or a placebo twice daily for five days. COVID-19 cases were first identified in December 2019 in <keyword id="208994" type="LOCATION" weightage="20" keywordseo="Wuhan">Wuhan</keyword>, Hubei Province, <keyword id="1334" type="LOCATION" weightage="20" keywordseo="China">China</keyword>. As of Saturday, more than 16 lakh people globally tested positive and more than one lakh have died. The United States has emerged as the hotspot with 20,000 deaths and 5.3 lakh cases.

Hydroxychloroquine consignment from India arrives in US

Kolkata, Apr 10 () City-based Bengal Chemicals andPharmaceutical Company on Friday received the license toproduce hydroxychloroquine, an anti-malarial drug that isbeing touted as 'game changer' in the fight against theCOVID-19 pandemic, a top company official said.The Drug Controller General of India allows BengalChemical to produce 200mg and 400mg hydroxychloroquinetablets, company Managing Director PM Chandraiah said."We are ready to do the formulation without any profitas a gesture to fight covid-19," Chandraiah said.The company can produce 10 lakh tablets a day and canramp it up to 15 lakhs, he said."But, the question is raw material. The government hasto arrange raw materials or active pharmaceutical ingredients(API). We have failed to arrange it from our end," Chandraiahsaid."We can start manufacturing in 2 days after receivingraw materials," another company official said. BSMNN NN

Bengal Chemicals gets license to produce hydroxychloroquine

New Delhi, April 7 () Indian pharma industry on Tuesday said there is enough stock of hydroxychloroquine in the country, and drug firms are ready to ramp up the production to meet domestic as well as export requirements.India has decided to partially lift the ban on the export of anti-malarial drug hydroxychloroquine in sync with its global commitment to deal with coronavirus pandemic.On March 25, India had banned the export of hydroxychloroquine in the midst of concerns that the drug could be used to fight COVID-19.India is the largest exporter of the drug.Officials said India would export the drug on a case-by-case basis after meeting all the domestic requirements."India manufactures 70 per cent of the world's supply of hydroxychloroquine. Companies like Zydus Cadila and IPCA are the major manufacturers of hydroxychloroquine in the country," Indian Pharmaceutical Alliance (IPA) Secretary General Sudarshan Jain told .The production capacity is sufficient to meet the current demand. If the need arises, the companies are committed to ramp up production, he added."The government has withdrawn the restrictions on 12 products and its formulations. Various scenarios are being assessed and it will be the endeavour to meet both the domestic demand and export obligation for Paracetamol and hydroxychloroquine," Jain said.The objective is to minimise speculative buying and hoarding in these trying times and ensure balance in distribution for patients and segment who need them, he added.In similar vein, Indian Drug Manufacturers' Association (IDMA) Executive Director Ashok Kumar Madan said: "India needs around 24 million tablets per year as on date for the three indications --- malaria, lupus and rheumatoid arthritis, it was being used".India currently has an annual installed capacity of around 40 metric tonne of active pharmaceutical ingredients (APIs) of hydroxychloroquine. With this capacity, "we can make around 200 million tablets of 200 mg," he added.So this indicates, that India currently has spare available capacity. Now, "we have to see how much would the country's requirements for the drug would grow for both treatment and prevention of COVID-19. The companies have already started ramping the capacity," Madan said.Hydroxychloroquine has suddenly come into limelight after the recommendation for the treatment and prevention of COVID-19, he added. The major API makers for the drug in the country are Zydus, Ipca and Mangalam Drugs. The major formulation makers of hydroxychloroquine are Ipca , Zydus, Wallace Pharmaceuticals and Cipla, Madan said.India exported hydroxycholoroquine API worth USD 1.22 billion in April-January 2019-20. During the same period exports of formulations made from hydroxycholoroquine was at USD 5.50 billion. RR AKT BAL

Enough capacity in country to meet hydroxychloroquine demand: Industry

<ul class="summary-list"><li>The doctor in <a href="https://www.businessinsider.com/stella-immanuel-member-tea-party-pro-trump-group-2020-7">the COVID-19 disinformation video endorsed by President Donald Trump</a> was accused of medical malpractice in a recent lawsuit, <a href="https://www.houstonchronicle.com/news/houston-texas/houston/article/houston-doctor-drug-viral-video-sued-louisiana-15443105.php">the Houston Chronicle reported on Wednesday</a>.</li><li>Citing court documents, the Chronicle said Dr. <keyword id="9662815" type="UNKNOWN" weightage="60" keywordseo="stella-immanuel">Stella Immanuel</keyword> was sued in Louisiana after a woman died shortly after leaving her care in 2019.</li><li>Immanuel shot to prominence on Monday after the president, his son Donald <keyword id="3669691" type="PERSON" weightage="60" keywordseo="trump-jr">Trump Jr</keyword>., and Madonna shared versions of a video of her touting an unproven <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> treatment.</li><li>In the video, Immanuel says that wearing masks isn't effective and that <keyword id="4751090" type="PERSON" weightage="60" keywordseo="Hydroxychloroquine">hydroxychloroquine</keyword> could cure COVID-19. Scientists have debunked both of those claims.</li><li>There is no cure for COVID-19, and the Food and Drug Administration has not approved it for use in coronavirus patients.</li></ul>Stella Immanuel, the doctor in <a href="https://www.businessinsider.com/stella-immanuel-member-tea-party-pro-trump-group-2020-7">the COVID-19 disinformation video endorsed by President Donald Trump</a>, was accused of medical malpractice in a recent lawsuit over a patient's death.Citing court documents, <a href="https://www.houstonchronicle.com/news/houston-texas/houston/article/houston-doctor-drug-viral-video-sued-louisiana-15443105.php">the Houston Chronicle reported on Wednesday</a> that Immanuel was sued in Louisiana after a woman died shortly after leaving Immanuel's care.According to the Chronicle, the lawsuit said the patient, identified as Leslie Norvell, had complained that a needle broke off in her arm while she was doing meth in 2019. It alleges that Immanuel and another doctor prescribed her medication but did not examine her arm closely and that Immanuel ignored Norvell's complaints.Norvell went home and later, because of the pain, went to a hospital, where a surgeon removed the broken needle. She died six days later.Immanuel rose to prominence this week after Trump tweeted a version of a video of her and a group of doctors calling themselves America's Frontline Doctors. The group, backed by the conservative Tea Party Patriots, has been <a href="https://www.businessinsider.com/stella-immanuel-member-tea-party-pro-trump-group-2020-7">critical of lockdown restrictions and other public-health measures</a>.In the video, they endorsed the malaria drug hydroxychloroquine as a cure for COVID-19 and said wearing masks wasn't effective. Scientists have <a href="https://www.factcheck.org/2020/07/in-viral-video-doctor-falsely-touts-hydroxychloroquine-as-covid-19-cure/">debunked</a> <a href="https://www.businessinsider.com/hydroxychloroquine-fails-covid-19-prevention-study-2020-7">both</a> of those <a href="https://www.businessinsider.com/face-masks-effective-in-protecting-against-coronavirus-2020-6">claims</a>.Other high-profile figures shared versions of the video on social media this week. Twitter <a href="https://www.businessinsider.com/twitter-suspends-activity-donald-trump-jr-account-hydroxychloroquine-video-2020-7">temporarily limited Donald Trump Jr's account</a>, saying it was for "spreading misleading or potentially harmful information." <a href="https://www.insider.com/instagram-flagged-madonna-viral-video-promoting-disinformation-about-covid-19-2020-7">Instagram labeled a video</a> of Immanuel posted by the pop singer Madonna as "false information."<a href="https://www.businessinsider.com/facebook-youtube-twitter-take-down-false-covid-video-shared-trump-2020-7">Facebook, YouTube, and Twitter took down the video</a>, prompting the president <a href="https://www.businessinsider.com/trump-censorship-claims-twitter-youtube-facebook-hydroxychloroquine-doctors-video-removed-2020-7">to retweet accusations of censorship</a>.<div type="image" title="donald trump hydroxychloroquine obsession 2x1" height="1200" width="2400" msid="77260194" hostid="261"></div>Trump has for months touted hydroxychloroquine as a potential COVID-19 treatment. In May, he said <a href="https://www.businessinsider.com/president-trump-says-hes-been-taking-hydroxychloroquine-2020-5">he was taking it as a precaution</a>.<a href="https://www.businessinsider.com/facebook-youtube-twitter-take-down-false-covid-video-shared-trump-2020-7"></a>The Food and Drug Administration in late March temporarily approved the drug for use in severe coronavirus cases, but it <a href="https://www.businessinsider.com/hydroxychloroquine-emergency-use-authorization-revoked-by-fda-2020-6">withdrew the waiver on June 15</a> after finding evidence that it could have harmful side effects. As of mid-June, the US government had <a href="https://www.businessinsider.com/hydroxychloroquine-us-surplus-fda-waiver-revoked-coronavirus-2020-6">more than 60 million surplus tablets</a> in storage, <a href="https://www.nytimes.com/2020/06/16/us/politics/trump-hydroxychloroquine-coronavirus.html?action=click&amp;module=Top%20Stories&amp;pgtype=HomepageHomepage">The New York Times reported</a>."Nobody needs to get sick," Immanuel said in the video, first broadcast by Breitbart, adding that "this virus has a cure." There is no cure for COVID-19.<div type="image" title="trump meeting with governors mask" height="919" width="1838" msid="77260196" hostid="261"></div><a href="https://www.thedailybeast.com/stella-immanuel-trumps-new-covid-doctor-believes-in-alien-dna-demon-sperm-and-hydroxychloroquine">The Daily Beast also reported this week</a> that Immanuel holds <a href="https://www.businessinsider.com/woman-in-viral-covid-19-video-fears-demon-sex-aliens-2020-7">several bizarre beliefs</a> about sex and religion.For example, Immanuel said in a 2013 church sermon that gynecological issues like cysts and endometriosis were a result of people dreaming about having sex with demons and witches.On Wednesday, Rudy Giuliani, an attorney for Trump, interviewed Immanuel on his radio show <a href="https://www.businessinsider.com/rudy-giuliani-stella-immanuel-demon-sperm-radio-hero-2020-7">and told her she was his "hero."</a>

Stella Immanuel, the doctor in the Trump-endorsed COVID-19 disinformation video, was accused of medical malpractice in a lawsuit after one of her patients died in 2019

<ul class="summary-list"><li>The US now has 66 million excess anti-malaria pills after <a href="https://www.businessinsider.com/hydroxychloroquine-emergency-use-authorization-revoked-by-fda-2020-6">the FDA U-turned</a> on <keyword id="1404150" type="PERSON" weightage="60" keywordseo="Chloroquine">chloroquine</keyword> and <keyword id="4751090" type="PERSON" weightage="60" keywordseo="Hydroxychloroquine">hydroxychloroquine</keyword>.</li><li>The <keyword id="6354656" type="ORGANIZATION" weightage="60" keywordseo="fda">FDA</keyword> said the drugs were likely ineffective in treating COVID-19, and could be dangerous. It previously allowed the drugs to be used in hospitalized <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> patients.</li><li>The government has sent out 31 million hydroxychloroquine tablets to state agencies, <a href="https://www.nytimes.com/2020/06/16/us/politics/trump-hydroxychloroquine-coronavirus.html?action=click&amp;module=Top%20Stories&amp;pgtype=HomepageHomepage">The New York Times reported</a>, and now has 63 million left over, alongside 3 million chloroquine pills.</li><li>Officials are now trying to figure out what to do with the excess drugs, and are working to "determine to available options," the Department of Health and Human Services said.</li><li>Dr. Rick Bright, the former head of the US Biomedical Advanced Research and Development Authority (BARDA), said they "should be destroyed."</li></ul>The US is sitting on a pile of 66 million anti-malaria pills after they were <a href="https://www.businessinsider.com/hydroxychloroquine-emergency-use-authorization-revoked-by-fda-2020-6">scrapped as a treatment for COVID-19</a> by the Food and Drug Administration (FDA).The FDA approved chloroquine and hydroxychloroquine for use on hospitalized COVID-19 patients on March 28 but <a href="https://www.businessinsider.com/hydroxychloroquine-emergency-use-authorization-revoked-by-fda-2020-6">revoked it</a> on Monday, less than three months later, following debate over their <a href="https://www.businessinsider.com/hydroxychloroquine-fails-to-prevent-coronavirus-study-in-nejm-2020-6">efficacy</a> and <a href="https://www.businessinsider.com/fda-guidelines-on-taking-hydroxychloroquine-to-treat-coronavirus-2020-5">safety</a>.<a href="https://www.fda.gov/media/138946/download"></a>The drugs "are unlikely to be effective in treating COVID-19" and can result in "serious" heart-related side effects, <a href="https://www.fda.gov/media/138946/download">the FDA said</a>. As of Monday, the US government had distributed 31 million hydroxychloroquine tablets from the Strategic National Stockpile to state health agencies, a Health and Human Services (HHS) spokesperson <a href="https://www.nytimes.com/2020/06/16/us/politics/trump-hydroxychloroquine-coronavirus.html?action=click&amp;module=Top%20Stories&amp;pgtype=HomepageHomepage">told The New York Times.</a><div type="image" title="los angeles california coronavirus hospital" height="750" width="1500" msid="76422791" hostid="261"></div>Sixty-three million hydroxychloroquine tablets remain in federal storage.Additionally, none of the 3 million doses of chloroquine gifted to the US by the German pharma giant Bayer in March were ever distributed, The Times reported.It is not yet known what will become of the federal stockpile.Officials are working with the drug donors to "determine the available options" for the excess pills, a HHS spokesperson told The Times.Dr Rick Bright, the former head of the US Biomedical Advanced Research and Development Authority (BARDA), <a href="https://twitter.com/RickABright/status/1272676989074276352">tweeted on Monday that the drugs</a> "should never have been brought into our country and should be destroyed."Hydroxychloroquine is still approved for use to treat malaria by the FDA, but it is unlikely that the US population will require as many as 66 million pills.<div type="image" title="U.S. President Donald Trump listens during a roundtable discussion on &quot;America's seniors&quot; in the Cabinet Room at the White House in Washington, U.S., June 15, 2020. REUTERS/Leah Millis" height="1967" width="3934" msid="76422794" hostid="261"></div>Trump, <a href="https://www.businessinsider.com/fda-guidelines-on-taking-hydroxychloroquine-to-treat-coronavirus-2020-5">who took hydroxychloroquine for two weeks</a>, did not approve of the FDA's decision to revoke the emergency waiver, saying on Monday it "certainly didn't hurt me."Peter Navarro, Trump's trade adviser, told The Times on Monday that the FDA U-turn was "a Deep State blindside by bureaucrats who hate the administration they work for."In May, France <a href="https://www.businessinsider.com/france-bans-hydroxychloroquine-for-treating-covid-19-2020-5">banned the use of hydroxychloroquine</a> to treat COVID-19, while the UK was <a href="https://www.businessinsider.com/coronavirus-uk-buying-donald-trump-hydroxychloroquine-tablets-treatment-covid-malaria-2020-5">seeking out 16 million pills</a> in case it turns out to be a successful treatment.

You Searched For "hydroxychloroquine tablet" and got 12 results

India biggest producer of 'game-changer' hydroxychloroquine drug; has enough capacity

PTI

What is Hydroxychloroquine medicine and how it could be a game changer

BI India Bureau

Pharma company founded by Indian-Americans donates hydroxychloroquine tablets in US

PTI

The UK is bulk-buying millions of hydroxychloroquine tablets in case Trump is right that it works against the coronavirus

Adam Payne

Govt plans supply of around 15.40 cr Hydroxychloroquine tablets in domestic market in April

PTI

Indian American's US pharma firm donates 3.4 M Hydroxychloroquine Sulphate tablets

PTI

Enough stock of hydroxychloroquine in India: Govt

PTI

Hydroxychloroquine consignment from India arrives in US

PTI

Bengal Chemicals gets license to produce hydroxychloroquine

PTI

Enough capacity in country to meet hydroxychloroquine demand: Industry

PTI

Stella Immanuel, the doctor in the Trump-endorsed COVID-19 disinformation video, was accused of medical malpractice in a lawsuit after one of her patients died in 2019

Bill Bostock

The US now has 66 million surplus anti-malaria pills after the FDA revoked an emergency waiver allowing chloroquine and hydroxychloroquine

Bill Bostock

Popular Keywords

Buying Guides